Clearmind Medicine Inc. filed a patent application in Hong Kong on March 13, 2026 for a novel combination of its MEAI platform with palmitoylethanolamide (PEA) to treat major depressive disorder. The filing builds on a partnership with NeuroThera Labs, a subsidiary of SciSparc Ltd., which supplies the PEA component.
The new patent expands Clearmind’s intellectual‑property portfolio beyond its existing alcohol‑use‑disorder focus and adds a depression indication that could tap a global market projected to exceed $25 billion by 2030. By securing protection in Hong Kong, the company positions itself to pursue regulatory approval and commercialization in the Asia‑Pacific region, where demand for novel depression treatments is rising.
Clearmind’s financial profile remains modest. As of the latest reporting period, the company posted a net loss of $3.85 million, recorded no revenue, and held $9.26 million in cash and cash equivalents. Management has acknowledged that these figures raise substantial doubt about the company’s ability to continue as a going concern, underscoring the importance of future product development and potential licensing opportunities.
The filing follows recent international patent applications for weight‑loss and fatty‑liver disease therapies, illustrating a concerted effort to cover a range of psychiatric and metabolic indications. The expanded portfolio strengthens Clearmind’s competitive moat and could enhance future licensing or partnership prospects in the mental‑health therapeutics arena.
Clearmind’s strategy to broaden its pipeline and secure intellectual property in key markets signals confidence in the long‑term value of its neuroplastogen platform. The MEAI‑PEA combination therapy represents a non‑hallucinogenic approach that may offer a safer and more affordable alternative to traditional antidepressants, potentially positioning the company as a notable player in the emerging psychedelic‑derived therapeutics space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.